My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

18.46 +0.09 (+0.49%)

Official Closing Price Updated: 7:00 PM EST, Feb 13, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

With Approval For Dengue Vaccine, Takeda May Find It Challenging To Compete Bigger Rivals: Report ↗

August 30, 2022

Via Benzinga

Benzinga Before The Bell: Elon Musk's Demand For Broad Twitter Data Dismissed, Xiaomi Wants To Join EV Race, Bed Bath & Beyond Plans To Share Turnaround Strategy Next Week And Other Top Financial Stories Friday, August 26 ↗

August 26, 2022

CNBC The Aviation Sector Is Slammed By Sky-High Rents

Via Benzinga

After Six Years Of Collaboration, Takeda Walks Away From Microbiome Drug Pact ↗

August 26, 2022

Via Benzinga

Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗

August 22, 2022

Via Benzinga

Takeda Touts Encouraging Data For Hyqvia In Rare Nerve Inflammation Disorder ↗

July 21, 2022

Via Benzinga

Takeda Pharma Clocks 1% Increase In FY21 Core Profit, Expects Growth Momentum In FY22 ↗

May 11, 2022

Via Benzinga

Why Pharvaris Stock Crashed — And Why At Least One Analyst Isn't Worried ↗

August 22, 2022

Shares hit their lowest point since November on the FDA's decision in HAE.

Via Investor's Business Daily

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

August 08, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has risen 18.18% since its last report. The company recently reported that it has 4.18 million shares sold...

Via Benzinga

EXCLUSIVE: Takeda's Cancer Partner BridGene Raises $38.5M To Accelerate Work On Undruggable Targets ↗

July 27, 2022

BridGene Biosciences Inc has completed a $38.5 million Series B financing by Lapam Capital, Junson Capital, and Dyee Capital. The platform enables screening small molecules against the whole proteome...

Via Benzinga

Novavax's COVID-19 Vaccine Gets Back To Back Approval In Japan, Australia For Adolescents ↗

July 26, 2022

Via Benzinga

Peering Into Takeda Pharmaceutical's Recent Short Interest ↗

July 21, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 15.38% since its last report. The company recently reported that it has 3.29 million shares sold short, which...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 19, 2022 ↗

July 19, 2022

Upgrades

Via Benzinga

Nestle Bets €40M On Enterome's Preclinical Food Allergy, IBD Hopeful ↗

July 18, 2022

Via Benzinga

Looking Into Takeda Pharmaceutical's Recent Short Interest ↗

July 05, 2022

Takeda Pharmaceutical's (NYSE:TAK) short percent of float has fallen 13.33% since its last report. The company recently reported that it has 4.06 million shares sold short, which...

Via Benzinga

Takeda's Hereditary Angioedema Treatment Prevents Attacks In Kids Below 12 Years ↗

July 01, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced late-breaking data from the Phase 3 SPRING study presented at the European Academy of Allergy and Clinical Immunology Hybrid Congress 2022.

Via Benzinga

Moderna Pops On Updated Booster Data, But Analyst Says It Needs A 'Second Act' ↗

June 08, 2022

Moderna tested a bivalent booster, which targets two Covid strains in one shot.

Via Investor's Business Daily

Quant Ratings Updated on 66 Stocks ↗

June 06, 2022

Out of the 66 stocks that were upgraded/downgraded this weekend, 12 were downgraded to a D-rating. And I'm giving you the first 10.

Via InvestorPlace

Current Report: Takeda Pharmaceutical ↗

May 18, 2022

Takeda’s price per share was $14.31 as of yesterday's market close. One year ago its price was $17.20.

Via Talk Markets

Takeda's Maribavir Reduces Hospitalization Rates, Hospital Stay In Post-Transplant Infection Patients ↗

April 22, 2022

Via Benzinga

Novavax Stock Looks Like a Good Value With Its New Combined Vaccine ↗

April 21, 2022

NVAX stock could be worth 63% more based on its new combination flu and Covid-19 vaccine after passing Phase 1/2 clinical trials.

Via InvestorPlace

Japan's Health Ministry Panel OKs Approval Of Novavax's COVID-19 Vaccine: Report ↗

April 18, 2022

Via Benzinga

Phathom Pharma's Vonoprazan Commercial Preparation Update At Needham Healthcare Conference ↗

April 13, 2022

Via Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Monday Markets News ↗

March 28, 2022

Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.

Via Talk Markets

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗

March 08, 2022

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...

Via Benzinga

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗

February 22, 2022

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...

Via Benzinga

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗

February 22, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...

Via Benzinga

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months ↗

February 18, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...

Via Benzinga

The Best Russell 2000 Stocks to Buy Before they Rebound ↗

February 15, 2022

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

Via InvestorPlace

Why Are Seagen Shares Sinking Today? ↗

February 10, 2022

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.